| answer text |
<p>The Department has made no assessment of the potential impact of application processing
delays by the Advisory Committee on Borderline Substances (ACBS) on patient choice
for malnutrition products and additional costs to the National Health Service.</p><p>Some
ACBS functions were put on hold from 2 April 2020 to 1 August 2020 owing to the COVID-19
pandemic. During that period, the Committee continued work on all applications that
were already being reviewed but did not accept new applications. Applications submitted
but not being reviewed before the period were reviewed upon the service resuming.</p><p>Borderline
substances indicated for the management of malnutrition and approved by the ACBS are
listed in Part XV of the Drug Tariff, in which there are currently 209 products listed
for the management of malnutrition.</p>
|
 |
